Alberto Gabizón
Impact in
- Biomaterials top 0.02%
- Nanoparticle-Based Drug Delivery
- Pharmaceutical Science top 0.2%
Papers in
- Biomaterials 83
- Nanoparticle-Based Drug Delivery 83
- Oncology 66
- Cancer Treatment and Pharmacology 28
- Co-authors
- Yechezkel BarenholzHilary ShmeedaDemetrios PapahadjopoulosFrancisco J. Plaza MartínAviva T. HorowitzDorit GorenSamuel ZalipskyY. Barenholz
- Journals
- Journal of Controlled Release (10 papers)Anti-Cancer Drugs (9 papers)Journal of Clinical Oncology (8 papers)Advanced Drug Delivery Reviews (6 papers)Journal of Liposome Research (6 papers)
- Partner nations
- IsraelUnited StatesUnited Kingdom
In The Last Decade
Alberto Gabizón
143 papers receiving 17.2k citations
Hit Papers
Peers
Comparison fields: 5 of 146
- Biomaterials 9.5k
- Pharmaceutical Science 1.0k
- Oncology 3.7k
- Biomedical Engineering 5.6k
- Molecular Biology 7.5k
Countries citing papers authored by Alberto Gabizón
This map shows the geographic impact of Alberto Gabizón's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alberto Gabizón with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alberto Gabizón more than expected).
Fields of papers citing papers by Alberto Gabizón
This network shows the impact of papers produced by Alberto Gabizón. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alberto Gabizón. The network helps show where Alberto Gabizón may publish in the future.
Co-authors
The 25 scholars most cited alongside Alberto Gabizón, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective Hit paper breakdown → | 2025 | 33 |
| 2 | 2024 | 6 | |
| 3 | 2023 | 3 | |
| 4 | 2020 | 59 | |
| 5 | 2018 | 48 | |
| 6 | 2018 | 20 | |
| 7 | 2017 | 38 | |
| 8 | 2016 | 25 | |
| 9 | Intracellular delivery of liposome-encapsulated zoledronic acid via folate receptor results in significant inhibition of tumor cell growth | 2007 | 1 |
| 10 | 2004 | 114 | |
| 11 | Pharmacokinetics of Pegylated Liposomal Doxorubicin Hit paper breakdown → | 2003 | 1317 |
| 12 | Folate receptor targeting of pegylated liposomal cisplatin enhances anti-tumor activity in mouse models without increasing toxicity | 2002 | 2 |
| 13 | 2002 | 39 | |
| 14 | 2000 | 156 | |
| 15 | Polyethylenglykol-umhülltes (pegyliertes) liposomales Doxorubicin: Grundlagen für die Anwendung bei soliden Tumoren | 1997 | 253 |
| 16 | 1993 | 69 | |
| 17 | 1991 | 115 | |
| 18 | 1990 | 48 | |
| 19 | 1985 | 77 | |
| 20 | Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. | 1982 | 221 |
About Alberto Gabizón
Alberto Gabizón is a scholar working on Biomaterials, Oncology, Radiology, Nuclear Medicine and Imaging, Cardiology and Cardiovascular Medicine and Toxicology, having authored 145 papers that have together received 17.7k indexed citations. Recurring topics across this work include Nanoparticle-Based Drug Delivery (83 papers), Nanoplatforms for cancer theranostics (31 papers), Cancer Treatment and Pharmacology (28 papers), Radiopharmaceutical Chemistry and Applications (21 papers), Chemotherapy-induced cardiotoxicity and mitigation (19 papers), RNA Interference and Gene Delivery (17 papers), Advanced biosensing and bioanalysis techniques (8 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). The work is most often cited by research in Biomaterials (9.5k citations), Pharmaceutical Science (1.0k citations), Oncology (3.7k citations), Biomedical Engineering (5.6k citations) and Molecular Biology (7.5k citations). Alberto Gabizón has collaborated with scholars based in Israel, United States and United Kingdom. Frequent co-authors include Yechezkel Barenholz, Hilary Shmeeda, Demetrios Papahadjopoulos, Francisco J. Plaza Martín, Aviva T. Horowitz, Dorit Goren, Samuel Zalipsky, Y. Barenholz, S.K. Huang and Dina Tzemach. Their work appears in journals such as Journal of Controlled Release, Anti-Cancer Drugs, Journal of Clinical Oncology, Advanced Drug Delivery Reviews and Journal of Liposome Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.